Abstract:e23029 Background: With the aging society was coming, more elderly nasopharyngeal carcinoma NPC patients should be pay attention. However, no guideline is proposed for them due to lack of prospective clinical trials. We aimed to use propensity score matching method to evaluate the survival outcome and toxicity of the different treatment modalities for them. Methods: II-IV(UICC 8th) elderly NPC patients (≥65 years) were retrospectively enrolled between 2004 to 2016 in our center. All the patients received definitive IMRT, and were allocated into radiotherapy only (RT), concurrent chemoradiotherapy (CCRT) and neoadjuvant chemotherapy followed with CCRT (NACT). Cisplatin-based chemotherapy was used. Survival outcomes and toxicity were analyzed using propensity score-matching method. Results: There were 142 patients included, and the median age was 68 years. The median follow-up time was 47 months. 23 patients received RT only, 61 patients received CCRT and 58 patients received NACT. After matching for gender, age, T and N stage, chemotherapy and non-chemotherapy patients (22 pairs) were analyzed and shown the chemotherapy group had a better OS (86% vs 68%, p= 0.031). The 3-years LRFS, DMFS and DFS of chemotherapy and non-chemotherapy was 95% and 85% ( p= 0.251), 95% and 86% ( p= 0.307), 86% and 73% ( p= 0.309). Furthermore, 41 pairs who underwent chemotherapy were sub-analyzed according to different modalities. CCRT group showed a comparable 3-years LRFS (100% vs 94%, p= 0.143), DMFS (87% vs 89%, p= 0.608), DFS (81% vs 84%, p= 0.892) and OS (79% vs 66%, p= 0.080) with NACT. For acute toxicity, the incidence of G3-5 bone marrow suppression in non-chemotherapy was significantly lower than chemotherapy group (8.7% vs 36.4%, p= 0.31), and the incidence of G3-5 mucositis was similar ( p= 0.517). Besides that, there was no significant difference in the incidence of G3-5 bone marrow suppression and mucositis between CCRT and NACT group ( p= 0.824, p= 0.618). Conclusions: Chemoradiotherapy could improve the survival rate of the elderly NPC patients compared with radiotherapy only. The acute toxicity of CCRT and NACT was similar and acceptable. CCRT was still the standard treatment modality for them. As for the elderly NPC patients who are in good performance status and comorbidity conditions, NACT might be also worthy of recommendation.

Selection and validation of chemotherapy beneficiaries among elderly nasopharyngeal carcinoma (NPC) patients treated with intensity-modulated radiation therapy (IMRT): a large real-world study

Concurrent Chemoradiotherapy versus Intensity-modulated Radiotherapy Alone for Elderly Nasopharyngeal Carcinoma Patients with Pre-treatment Epstein-Barr Virus DNA: A Cohort Study in an Endemic Area with Long-term Follow-up.

Risk stratification and beneficiary selection among elderly nasopharyngeal carcinoma patients from concurrent chemoradiotherapy combined with induction chemotherapy

Significance of chemotherapy for older patients with nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A propensity score matching analysis

Elderly nasopharyngeal carcinoma patients (aged ≥70 years): Survival and treatment strategies

Selection and Validation of Induction Chemotherapy Beneficiaries among Patients with T3N0, T3N1, T4N0 Nasopharyngeal Carcinoma Using Epstein-Barr Virus DNA: A Joint Analysis of Real-World and Clinical Trial Data

Propensity Score Matching Analysis of the Survival Outcome and Toxicity of Different Treatment Modalities for the Elderly Nasopharyngeal Carcinoma Patients.

Prognostic model on overall survival in elderly nasopharyngeal carcinoma patients: a recursive partitioning analysis identifying pre-treatment risk stratification

Clinical Characteristics and Prognosis of Elderly Nasopharyngeal Carcinoma Patients Receiving Intensity-Modulated Radiotherapy Only

The Characteristics and Survival Outcomes in Patients Aged 70 Years and Older with Nasopharyngeal Carcinoma in the Intensity-Modulated Radiotherapy Era

A matched cohort study of standard chemo-radiotherapy versus radiotherapy alone in elderly nasopharyngeal carcinoma patients

Feasibility and Efficacy of Chemoradiotherapy for Elderly Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: Results from a Matched Cohort Analysis

Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: Analysis of 9468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial

Neoadjuvant chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in elderly patients with stage III‐IVa nasopharyngeal carcinoma: A real‐world study based on medical comorbidities

Concurrent chemoradiotherapy versus radiotherapy alone in older patients with stage II Nasopharyngeal Carcinoma after Intensity-Modulated Radiotherapy: a propensity score-matched cohort study

Lobaplatin-based concurrent chemoradiotherapy in elderly nasopharyngeal carcinoma

The Impact of Adult Comorbidity Evaluation-27 on the Clinical Outcome of Elderly Nasopharyngeal Carcinoma Patients Treated with Chemoradiotherapy or Radiotherapy: a Matched Cohort Analysis.

Long-term Survivals, Toxicities and the Role of Chemotherapy in Early-Stage Nasopharyngeal Carcinoma Patients Treated with Intensity-Modulated Radiation Therapy: A Retrospective Study with 15-Year Follow-up

Identifying optimal clinical trial candidates for locoregionally advanced nasopharyngeal carcinoma: Analysis of 9,468 real-world cases and validation by two phase 3 multicentre, randomised controlled trial

Therapeutic effect of radiotherapy and chemotherapy in 202 elderly patients with nasopharyngeal carcinoma

The effect of adding concurrent chemotherapy to radiotherapy for stage II nasopharyngeal carcinoma with undetectable pretreatment Epstein-Barr virus DNA: Retrospective analysis with a large institutional-based cohort